Summary: This podcast focuses on the specialized needs of manufacturing cell therapies at scale and how Custom Manufacturing Organizations are stepping in to drive process efficiencies and standardization.

Summary: During this talk, we share the latest data leveraging GPEx Lightning to generate highly stable, highly productive cell pools and discuss how the GPEx suite of technologies can be tailored to the specific needs of each individual program on its path to clinical trials.

Summary: Learn how Catalent Cell & Gene Therapy recognizes the challenges faced when obtaining raw materials, and how our investments in pDNA manufacturing secure our integrated supply chain.

Summary: Learn how integrated service providers can streamline manufacturing, development and commercialization for optimal regulatory and process outcomes for gene therapy programs.

Summary: Along with the complexities of vaccine and viral-based gene therapy process development comes the need for analytical techniques that can help assess quality parameters, in real-time.

Summary: In this executive summary, our expert discusses how Catalent Cell & Gene Therapy continues to learn about formulating gene therapies by adapting methods used for other biologics.

Summary: In this on-demand webinar, our expert discusses how Catalent Cell and Gene Therapy is working towards an approach for gathering product knowledge and establishing formulation selection criteria using traditional/routine techniques as well as evaluating novel methodologies for gene therapy products.

Summary: Dr. Mahdavi’s talk reviews key growth areas, innovative technologies and future strategies designed to increase the efficiency and scalability of advanced therapeutics.

Summary: In this webinar, leaders in the field discuss new vaccines and drugs that have resulted from COVID and key learnings to prepare for the next pandemic.

Summary: This roundtable discussion offers a closer look at oncology's hottest fields, including CAR-T and precision medicine, 2021's biggest research trends and the data they're most looking forward to seeing.